|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCSK7 |
Gene summary for PCSK7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCSK7 | Gene ID | 9159 |
| Gene name | proprotein convertase subtilisin/kexin type 7 | |
| Gene Alias | LPC | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q16549 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9159 | PCSK7 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.22e-12 | 6.48e-01 | -0.1954 |
| 9159 | PCSK7 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.63e-04 | 5.39e-01 | -0.1526 |
| 9159 | PCSK7 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.84e-10 | 6.39e-01 | -0.1464 |
| 9159 | PCSK7 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.17e-03 | 4.68e-01 | -0.1001 |
| 9159 | PCSK7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.83e-04 | 5.51e-01 | -0.059 |
| 9159 | PCSK7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.22e-04 | -2.86e-01 | 0.294 |
| 9159 | PCSK7 | A015-C-203 | Human | Colorectum | FAP | 3.19e-27 | -3.28e-01 | -0.1294 |
| 9159 | PCSK7 | A015-C-204 | Human | Colorectum | FAP | 6.98e-03 | -1.78e-01 | -0.0228 |
| 9159 | PCSK7 | A014-C-040 | Human | Colorectum | FAP | 5.45e-04 | -4.73e-01 | -0.1184 |
| 9159 | PCSK7 | A002-C-201 | Human | Colorectum | FAP | 2.75e-09 | -2.99e-01 | 0.0324 |
| 9159 | PCSK7 | A002-C-203 | Human | Colorectum | FAP | 1.29e-04 | -8.00e-02 | 0.2786 |
| 9159 | PCSK7 | A001-C-119 | Human | Colorectum | FAP | 1.42e-08 | -4.54e-01 | -0.1557 |
| 9159 | PCSK7 | A001-C-108 | Human | Colorectum | FAP | 4.54e-15 | -3.00e-01 | -0.0272 |
| 9159 | PCSK7 | A002-C-205 | Human | Colorectum | FAP | 2.00e-18 | -4.36e-01 | -0.1236 |
| 9159 | PCSK7 | A001-C-104 | Human | Colorectum | FAP | 3.85e-03 | -1.97e-01 | 0.0184 |
| 9159 | PCSK7 | A015-C-006 | Human | Colorectum | FAP | 6.88e-13 | -4.91e-01 | -0.0994 |
| 9159 | PCSK7 | A015-C-106 | Human | Colorectum | FAP | 1.19e-09 | -1.91e-01 | -0.0511 |
| 9159 | PCSK7 | A002-C-114 | Human | Colorectum | FAP | 2.88e-14 | -4.37e-01 | -0.1561 |
| 9159 | PCSK7 | A015-C-104 | Human | Colorectum | FAP | 2.37e-31 | -3.90e-01 | -0.1899 |
| 9159 | PCSK7 | A001-C-014 | Human | Colorectum | FAP | 1.03e-17 | -3.60e-01 | 0.0135 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
| GO:0016485 | Colorectum | AD | protein processing | 63/3918 | 225/18723 | 6.77e-03 | 4.19e-02 | 63 |
| GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
| GO:00164851 | Colorectum | SER | protein processing | 55/2897 | 225/18723 | 2.84e-04 | 4.67e-03 | 55 |
| GO:00516042 | Colorectum | MSS | protein maturation | 75/3467 | 294/18723 | 1.70e-03 | 1.53e-02 | 75 |
| GO:00164852 | Colorectum | MSS | protein processing | 57/3467 | 225/18723 | 6.60e-03 | 4.38e-02 | 57 |
| GO:00516044 | Colorectum | CRC | protein maturation | 47/2078 | 294/18723 | 6.52e-03 | 4.70e-02 | 47 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
| GO:00516046 | Liver | Cirrhotic | protein maturation | 121/4634 | 294/18723 | 3.54e-10 | 1.68e-08 | 121 |
| GO:00164853 | Liver | Cirrhotic | protein processing | 85/4634 | 225/18723 | 9.01e-06 | 1.32e-04 | 85 |
| GO:004244511 | Liver | Cirrhotic | hormone metabolic process | 73/4634 | 218/18723 | 2.22e-03 | 1.36e-02 | 73 |
| GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
| GO:001648511 | Liver | HCC | protein processing | 121/7958 | 225/18723 | 4.01e-04 | 2.71e-03 | 121 |
| GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
| GO:00164856 | Oral cavity | OSCC | protein processing | 121/7305 | 225/18723 | 4.56e-06 | 5.23e-05 | 121 |
| GO:005160416 | Oral cavity | LP | protein maturation | 122/4623 | 294/18723 | 1.37e-10 | 7.72e-09 | 122 |
| GO:001648513 | Oral cavity | LP | protein processing | 83/4623 | 225/18723 | 2.87e-05 | 4.52e-04 | 83 |
| GO:005160432 | Oral cavity | NEOLP | protein maturation | 50/2005 | 294/18723 | 6.46e-04 | 5.47e-03 | 50 |
| GO:001648521 | Oral cavity | NEOLP | protein processing | 39/2005 | 225/18723 | 1.68e-03 | 1.17e-02 | 39 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCSK7 | SNV | Missense_Mutation | rs775499699 | c.1679N>A | p.Arg560His | p.R560H | Q16549 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCSK7 | SNV | Missense_Mutation | c.1337N>T | p.Arg446Leu | p.R446L | Q16549 | protein_coding | tolerated(0.31) | benign(0.059) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| PCSK7 | SNV | Missense_Mutation | c.133N>C | p.Asp45His | p.D45H | Q16549 | protein_coding | tolerated_low_confidence(0.11) | benign(0.037) | TCGA-DG-A2KH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCSK7 | SNV | Missense_Mutation | c.2114N>G | p.His705Arg | p.H705R | Q16549 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-EA-A4BA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| PCSK7 | SNV | Missense_Mutation | c.1342N>C | p.Glu448Gln | p.E448Q | Q16549 | protein_coding | deleterious(0.02) | benign(0.045) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PCSK7 | SNV | Missense_Mutation | c.1058N>T | p.Ala353Val | p.A353V | Q16549 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-FU-A3TX-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PCSK7 | SNV | Missense_Mutation | novel | c.283N>G | p.His95Asp | p.H95D | Q16549 | protein_coding | tolerated(0.09) | possibly_damaging(0.649) | TCGA-A6-5659-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PCSK7 | SNV | Missense_Mutation | rs199777458 | c.692N>A | p.Arg231Gln | p.R231Q | Q16549 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| PCSK7 | SNV | Missense_Mutation | c.356N>T | p.Ala119Val | p.A119V | Q16549 | protein_coding | tolerated(0.23) | benign(0.013) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| PCSK7 | SNV | Missense_Mutation | c.1535N>C | p.Val512Ala | p.V512A | Q16549 | protein_coding | tolerated(0.06) | possibly_damaging(0.604) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9159 | PCSK7 | ENZYME, PROTEASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 252166868 | ||
| 9159 | PCSK7 | ENZYME, PROTEASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 252166858 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |